Agencourt Bioscience has launched an expanded SNP-discovery service for pre-validated sequencing assays of kinases.
The company has also said it has licensed the new service to the Dana-Farber Cancer Institute, which will use it to sequence assays developed by cancer researchers Matthew Meyerson, and William Sellers. For this deal, Agencourt will offer both pre-validated sequencing assays and a kinase-discovery program in which polymorphisms in more than 92 kinases have previously been mapped. Financial terms of the licensing agreement were not released.